DaVita (NYSE:DVA) Sets New 12-Month Low – What’s Next?

DaVita Inc. (NYSE:DVA)’s share price reached a new 52-week low during trading on Wednesday . The stock traded as low as $113.12 and last traded at $113.5920, with a volume of 38268 shares. The stock had previously closed at $114.72.

Analyst Upgrades and Downgrades

Several equities research analysts have commented on the company. Truist Financial set a $140.00 price objective on DaVita in a research report on Tuesday, October 14th. Bank of America decreased their target price on shares of DaVita from $145.00 to $140.00 and set an “underperform” rating for the company in a research note on Wednesday, September 10th. Weiss Ratings reissued a “hold (c)” rating on shares of DaVita in a report on Monday. TD Cowen cut their price objective on shares of DaVita from $154.00 to $133.00 and set a “hold” rating for the company in a report on Monday, November 3rd. Finally, UBS Group reiterated a “buy” rating on shares of DaVita in a research report on Monday, December 15th. One investment analyst has rated the stock with a Buy rating, six have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $148.00.

DaVita Price Performance

The company’s fifty day simple moving average is $120.99 and its 200-day simple moving average is $131.09. The firm has a market capitalization of $8.03 billion, a PE ratio of 11.69, a P/E/G ratio of 0.88 and a beta of 1.00.

DaVita (NYSE:DVA) last issued its quarterly earnings results on Wednesday, October 29th. The company reported $2.51 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $3.17 by ($0.66). DaVita had a negative return on equity of 13,370.89% and a net margin of 5.80%.The firm had revenue of $3.42 billion during the quarter, compared to analyst estimates of $3.43 billion. During the same period in the prior year, the firm earned $2.59 earnings per share. The business’s revenue was up 4.8% on a year-over-year basis. DaVita has set its FY 2025 guidance at 10.350-11.150 EPS. Analysts forecast that DaVita Inc. will post 10.76 earnings per share for the current year.

Institutional Trading of DaVita

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Hudson Bay Capital Management LP increased its stake in DaVita by 55.5% during the third quarter. Hudson Bay Capital Management LP now owns 2,613 shares of the company’s stock worth $347,000 after acquiring an additional 933 shares during the last quarter. Allworth Financial LP grew its holdings in shares of DaVita by 311.7% during the 3rd quarter. Allworth Financial LP now owns 564 shares of the company’s stock worth $75,000 after purchasing an additional 427 shares during the period. Swiss Life Asset Management Ltd increased its position in shares of DaVita by 4.3% during the 3rd quarter. Swiss Life Asset Management Ltd now owns 7,278 shares of the company’s stock worth $967,000 after purchasing an additional 300 shares during the last quarter. CIBC Private Wealth Group LLC raised its holdings in DaVita by 19.7% in the 3rd quarter. CIBC Private Wealth Group LLC now owns 2,628 shares of the company’s stock valued at $349,000 after buying an additional 432 shares during the period. Finally, CIBC Bancorp USA Inc. acquired a new position in DaVita in the third quarter valued at about $683,000. Institutional investors and hedge funds own 90.12% of the company’s stock.

About DaVita

DaVita Inc (NYSE: DVA) is a leading provider of kidney care services, specializing in the management and operation of outpatient dialysis centers for patients with chronic kidney failure and end-stage renal disease. Headquartered in Denver, Colorado, the company offers a comprehensive suite of treatment modalities, including in-center hemodialysis, peritoneal dialysis, and home dialysis therapies. In addition to its core dialysis services, DaVita provides patient education, nutritional counseling, vascular access management and related laboratory services to support kidney health and overall patient well-being.

Since its formation in the mid-1990s through a clinical management services spin-off, DaVita has expanded both organically and through strategic partnerships and acquisitions.